Hemianopic and quadrantanopic safe to drive

Article

Hemianopic and quadrantanopic people have been declared safe to drive because they make more head movements into their blind field to compensate, according to a recent study published in Investigative Ophthalmology and Visual Science.

Hemianopic and quadrantanopic people have been declared safe to drive because they make more head movements into their blind field to compensate, according to a recent study published in Investigative Ophthalmology and Visual Science.

A team led by Joanne M. Wood et al., Queensland University of Technology, Queensland, Australia, studied eye and head movements and lane keeping in 22 participants with homonymous hemianopic defects, 8 participants with quadrantanopic defects and 30 participants with normal vision fields. All participants drove a 6.3 mile route and were objectively assessed on speed, acceleration, braking and cornering.

Findings showed that hemianopic and quadrantanopic people took more care when cornering, accelerating and braking. Lane position stability and eye movement was superior in those who were rated as safe to drive.

The study suggested that the characteristics demonstrated by the participants could be trained in rehabilitation programs to improve safety in the population.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.